LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 102

Search options

  1. Article ; Online: Exosomes as emerging nanoplatform in cancer therapy.

    Aqil, Farrukh / Gupta, Ramesh

    Cancer letters

    2023  Volume 574, Page(s) 216394

    MeSH term(s) Humans ; Exosomes ; Cell Line, Tumor ; Nanoparticles ; Neoplasms/drug therapy
    Language English
    Publishing date 2023-09-15
    Publishing country Ireland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 195674-7
    ISSN 1872-7980 ; 0304-3835
    ISSN (online) 1872-7980
    ISSN 0304-3835
    DOI 10.1016/j.canlet.2023.216394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Exosomes in Cancer Therapy.

    Aqil, Farrukh / Gupta, Ramesh C

    Cancers

    2022  Volume 14, Issue 3

    Abstract: Exosomes or small extracellular vesicles (EVs) are natural nanoparticles and known to play essential roles in intercellular communications, carrying a cargo of a broad variety of lipids, proteins, metabolites, RNAs (mRNA, miRNA, tRNA, long non-coding RNA) ...

    Abstract Exosomes or small extracellular vesicles (EVs) are natural nanoparticles and known to play essential roles in intercellular communications, carrying a cargo of a broad variety of lipids, proteins, metabolites, RNAs (mRNA, miRNA, tRNA, long non-coding RNA), and DNAs (mtDNA, ssDNA, dsDNA) [...].
    Language English
    Publishing date 2022-01-20
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14030500
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy.

    Wallen, Margaret / Aqil, Farrukh / Spencer, Wendy / Gupta, Ramesh C

    Pharmaceutics

    2023  Volume 15, Issue 7

    Abstract: Despite its introduction more than three decades ago, gene therapy has fallen short of its expected potential for the treatment of a broad spectrum of diseases and continues to lack widespread clinical use. The fundamental limitation in clinical ... ...

    Abstract Despite its introduction more than three decades ago, gene therapy has fallen short of its expected potential for the treatment of a broad spectrum of diseases and continues to lack widespread clinical use. The fundamental limitation in clinical translatability of this therapeutic modality has always been an effective delivery system that circumvents degradation of the therapeutic nucleic acids, ensuring they reach the intended disease target. Plasmid DNA (pDNA) for the purpose of introducing exogenous genes presents an additional challenge due to its size and potential immunogenicity. Current pDNA methods include naked pDNA accompanied by electroporation or ultrasound, liposomes, other nanoparticles, and cell-penetrating peptides, to name a few. While the topic of numerous reviews, each of these methods has its own unique set of limitations, side effects, and efficacy concerns. In this review, we highlight emerging uses of exosomes for the delivery of pDNA for gene therapy. We specifically focus on bovine milk and colostrum-derived exosomes as a nano-delivery "platform". Milk/colostrum represents an abundant, scalable, and cost-effective natural source of exosomes that can be loaded with nucleic acids for targeted delivery to a variety of tissue types in the body. These nanoparticles can be functionalized and loaded with pDNA for the exogenous expression of genes to target a wide variety of disease phenotypes, overcoming many of the limitations of current gene therapy delivery techniques.
    Language English
    Publishing date 2023-06-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics15071832
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Milk/colostrum exosomes: A nanoplatform advancing delivery of cancer therapeutics.

    Wallen, Margaret / Aqil, Farrukh / Spencer, Wendy / Gupta, Ramesh C

    Cancer letters

    2023  Volume 561, Page(s) 216141

    Abstract: Chemotherapeutics continue to play a central role in the treatment of a wide variety of cancers. Conventional chemotherapy involving bolus intravenous doses results in severe side effects - in some cases life threatening - delayed toxicity and ... ...

    Abstract Chemotherapeutics continue to play a central role in the treatment of a wide variety of cancers. Conventional chemotherapy involving bolus intravenous doses results in severe side effects - in some cases life threatening - delayed toxicity and compromised quality-of-life. Attempts to deliver small drug molecules using liposomes, polymeric nanoparticles, micelles, lipid nanoparticles, etc. have produced limited nanoformulations for clinical use, presumably due to a lack of biocompatibility of the material, costs, toxicity, scalability, and/or lack of effective administration. Naturally occurring small extracellular vesicles, or exosomes, may offer a solution and a viable system for delivering cancer therapeutics. Combined with their inherent trafficking ability and versatility of cargo capacity, exosomes can be engineered to specifically target cancerous cells, thereby minimizing off-target effects, and increasing the efficacy of cancer therapeutics. Exosomal formulations have mitigated the toxic effects of several drugs in murine cancer models. In this article, we review studies related to exosomal delivery of both small molecules and biologics, including siRNA to inhibit specific gene expression, in the pursuit of effective cancer therapeutics. We focus primarily on bovine milk and colostrum exosomes as the cancer therapeutic delivery vehicles based on their high abundance, cost effectiveness, scalability, high drug loading, functionalization of exosomes for targeted delivery, and lack of toxicity. While bovine milk exosomes may provide a new platform for drug delivery, extensive comparison to other nanoformulations and evaluation of long-term toxicity will be required to fully realize its potential.
    MeSH term(s) Female ; Pregnancy ; Humans ; Animals ; Mice ; Milk ; Colostrum/metabolism ; Exosomes/metabolism ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Drug Delivery Systems
    Language English
    Publishing date 2023-03-22
    Publishing country Ireland
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 195674-7
    ISSN 1872-7980 ; 0304-3835
    ISSN (online) 1872-7980
    ISSN 0304-3835
    DOI 10.1016/j.canlet.2023.216141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Advances in lipid-based carriers for cancer therapeutics: Liposomes, exosomes and hybrid exosomes.

    Moholkar, Disha N / Kandimalla, Raghuram / Gupta, Ramesh C / Aqil, Farrukh

    Cancer letters

    2023  Volume 565, Page(s) 216220

    Abstract: Cancer has recently surpassed heart disease as the leading cause of deaths worldwide for the age group 45-65 and has been the primary focus for biomedical researchers. Presently, the drugs involved in the first-line cancer therapy are raising concerns ... ...

    Abstract Cancer has recently surpassed heart disease as the leading cause of deaths worldwide for the age group 45-65 and has been the primary focus for biomedical researchers. Presently, the drugs involved in the first-line cancer therapy are raising concerns due to high toxicity and lack of selectivity to cancer cells. There has been a significant increase in research with innovative nano formulations to entrap the therapeutic payload to enhance efficacy and eliminate or minimize toxic effects. Lipid-based carriers stand out due to their unique structural properties and biocompatible nature. The two main leaders of lipid-based drug carriers: long known liposomes and comparatively new exosomes have been well-researched. The similarity between the two lipid-based carriers is the vesicular structure with the core's capability to carry the payload. While liposomes utilize chemically derived and altered phospholipid components, the exosomes are naturally occurring vesicles with inherent lipids, proteins, and nucleic acids. More recently, researchers have focused on developing hybrid exosomes by fusing liposomes and exosomes. Combining these two types of vesicles may offer some advantages such as high drug loading, targeted cellular uptake, biocompatibility, controlled release, stability in harsh conditions and low immunogenicity.
    MeSH term(s) Humans ; Liposomes/chemistry ; Exosomes/metabolism ; Drug Carriers ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Phospholipids/metabolism ; Drug Delivery Systems
    Chemical Substances Liposomes ; Drug Carriers ; Phospholipids
    Language English
    Publishing date 2023-05-19
    Publishing country Ireland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 195674-7
    ISSN 1872-7980 ; 0304-3835
    ISSN (online) 1872-7980
    ISSN 0304-3835
    DOI 10.1016/j.canlet.2023.216220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Editorial: Role of Phytochemicals and Structural Analogs in Cancer Chemoprevention and Therapeutics.

    Arif, Jamal M / Kandimalla, Raghuram / Aqil, Farrukh

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 865619

    Language English
    Publishing date 2022-03-16
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.865619
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Updates on the anticancer potential of garlic organosulfur compounds and their nanoformulations: Plant therapeutics in cancer management.

    Pandey, Pratibha / Khan, Fahad / Alshammari, Nawaf / Saeed, Amir / Aqil, Farrukh / Saeed, Mohd

    Frontiers in pharmacology

    2023  Volume 14, Page(s) 1154034

    Abstract: Garlic ( ...

    Abstract Garlic (
    Language English
    Publishing date 2023-03-20
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2023.1154034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Milk exosomes: A biogenic nanocarrier for small molecules and macromolecules to combat cancer.

    Kandimalla, Raghuram / Aqil, Farrukh / Tyagi, Neha / Gupta, Ramesh

    American journal of reproductive immunology (New York, N.Y. : 1989)

    2020  Volume 85, Issue 2, Page(s) e13349

    Abstract: Exosomes are unique biogenic nanocarriers of endocytic origin that are generated from most of the cells and found in biofluids like milk, plasma, saliva, and urine. Bovine milk represents the largest and an economic source for the production of exosomes. ...

    Abstract Exosomes are unique biogenic nanocarriers of endocytic origin that are generated from most of the cells and found in biofluids like milk, plasma, saliva, and urine. Bovine milk represents the largest and an economic source for the production of exosomes. In recent past, the utility of the milk exosomes as drug carriers is intensified. Exosomes are emerging for delivery of both small and large therapeutics due to their biocompatibility. In this article, we highlighted the various exosomal isolation techniques, physicochemical properties, their biodistribution, and utility of milk exosomes in delivering the small drug molecules and siRNA to combat cancer.
    MeSH term(s) Animals ; Antineoplastic Agents/therapeutic use ; Biological Therapy/methods ; Drug Delivery Systems/methods ; Exosomes/metabolism ; Humans ; Milk/metabolism ; Nanostructures ; Neoplasms/therapy ; RNA, Small Interfering/therapeutic use
    Chemical Substances Antineoplastic Agents ; RNA, Small Interfering
    Language English
    Publishing date 2020-10-06
    Publishing country Denmark
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 604542-x
    ISSN 1600-0897 ; 0271-7352 ; 8755-8920 ; 1046-7408
    ISSN (online) 1600-0897
    ISSN 0271-7352 ; 8755-8920 ; 1046-7408
    DOI 10.1111/aji.13349
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Exosome-based approaches in the management of Alzheimer's disease.

    Kandimalla, Raghuram / Saeed, Mohd / Tyagi, Neetu / Gupta, Ramesh C / Aqil, Farrukh

    Neuroscience and biobehavioral reviews

    2022  Volume 144, Page(s) 104974

    Abstract: Alzheimer's disease (AD) has been the most extensively studied neurological disorders that affects millions of individuals globally and is associated with misfolding of proteins in the brain. Amyloid-β and tau are predominantly involved in the ... ...

    Abstract Alzheimer's disease (AD) has been the most extensively studied neurological disorders that affects millions of individuals globally and is associated with misfolding of proteins in the brain. Amyloid-β and tau are predominantly involved in the pathogenesis of AD. Therapeutic interventions and nanotechnological advancements are useful only in managing the AD symptoms and the cure for this disease remains elusive. Exosomes, originating from most cell and tissue types are regarded as a double-edged sword, considering their roles in the progression and treatment of AD. Exosomes can be manipulated as drug delivery vehicles for a wide range of therapeutic cargos-both small molecules and macromolecules. Herein, we review the roles of exosomes in the pathology, diagnosis, and treatment of AD and highlight their application as a drug carrier to the brain for AD treatment.
    MeSH term(s) Humans ; Alzheimer Disease/metabolism ; Exosomes/metabolism ; Exosomes/pathology ; Amyloid beta-Peptides/metabolism ; Brain/metabolism ; tau Proteins/metabolism
    Chemical Substances Amyloid beta-Peptides ; tau Proteins
    Language English
    Publishing date 2022-11-23
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 282464-4
    ISSN 1873-7528 ; 0149-7634
    ISSN (online) 1873-7528
    ISSN 0149-7634
    DOI 10.1016/j.neubiorev.2022.104974
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Molecular interactions of cucurbitacins A and B with anaplastic lymphoma kinase for lung cancer treatment.

    Saeed, Mohd / Alshammari, Nawaf / Saeed, Amir / Ayyed Al-Shammary, Asma / Alabdallah, Nadiyah M / Ahmad, Irfan / Aqil, Farrukh

    Journal of biomolecular structure & dynamics

    2023  , Page(s) 1–9

    Abstract: Lung cancer is a major global public health issue and the leading cause of cancer-related deaths. Several medications are commonly used to treat lung cancer, either alone or in combination with other treatments. The anaplastic lymphoma kinase (ALK) ... ...

    Abstract Lung cancer is a major global public health issue and the leading cause of cancer-related deaths. Several medications are commonly used to treat lung cancer, either alone or in combination with other treatments. The anaplastic lymphoma kinase (ALK) protein is one of several target proteins that are thought to be potential therapeutic targets in the context of lung cancer. Several ALK inhibitors have been identified, but many of these have been associated with side effects and toxicity concerns. In this study, we intend to computationally predict the binding potential of cucurbitacins (CBNs), A and B to the active pockets of ALK, in order to estimate their potential ALK inhibitors. Compared to CBN-A, which has a binding energy of -7.9 kcal/mol, CBN B exhibits significantly better binding efficacy with a binding energy of -8.1 kcal/mol. This is closely comparable to the binding energy of Crizotinib, which is -8.2 kcal/mol. The results of the molecular dynamics simulation indicated that the docked complexes remained stable for the duration of the 100 ns simulation period. CBN inhibited the proliferation of both non-small cell lung cancer cell lines, H1299 and A549, in a dose-dependent manner. CBN-B inhibited the proliferation of lung cancer cells, showing IC50 values of 0.08 µM for H1299 cells and 0.10 µM for A549 cells. The computational analyses provide strong evidence that CBN-B has the potential to act as a potent natural inhibitor against ALK, and could prove to be a valuable treatment option for lung cancer.Communicated by Ramaswamy H. Sarma.
    Language English
    Publishing date 2023-11-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 49157-3
    ISSN 1538-0254 ; 0739-1102
    ISSN (online) 1538-0254
    ISSN 0739-1102
    DOI 10.1080/07391102.2023.2274976
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top